Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
The presentation, "PROTECT II: A Prospective Multicenter Trial Comparing Impella to Intra-Aortic Balloon Pump in High-Risk PCI" is scheduled for Friday, May 20, between 9:10 a.m. - 12:10 p.m. CEST in Room 342AB at the Palais des Congres de Paris.
PROTECT II was a prospective multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high-risk percutaneous coronary intervention (PCI).
Many Americans unaware of heart disease risks during pregnancy